Adventures in Capitalism: Outcry Over EpiPen Prices Hasn’t Made Them Lower

Sunday, June 4, 2017 - 16:11 in Mathematics & Economics

Mylan has an effective monopoly on a lifesaving product, which has allowed its leaders to see public outrage as a tax they must pay.

Read the whole article on NY Times Health

More from NY Times Health

Latest Science Newsletter

Get the latest and most popular science news articles of the week in your Inbox! It's free!

Check out our next project, Biology.Net